CoChat

Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor

Open access
Bertini, R, Barcelos, LS, Beccari, AR, Cavalieri, B, Moriconi, A, Bizzarri, C, Di Benedetto, P, Di Giacinto, C, Gloaguen, I, Galliera, E, Corsi, MM, Russo, RC, Andrade, SP, Cesta, MC, Nano, G, Aramini, A, Cutrin, JC, Locati, M, Allegretti, M, Teixeira, MM · 2012 · British Journal of Pharmacology
Cited by 74

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE DF 2156A is a new dual inhibitor of IL‐8 receptors CXCR1 and CXCR2 with an optimal pharmacokinetic profile. We characterized its binding mode, molecular mechanism of action and selectivity, and evaluated its therapeutic potential. EXPERIMENTAL APPROACH The binding mode, molecular mechanism of action and selectivity were investigated using chemotaxis of L1.2 transfectants and human leucocytes, in addition to radioligand and [35 S]‐GTPγS binding approaches. The therapeutic potential of DF 2156A was evaluated in acute (liver ischaemia and reperfusion) and chronic (sponge‐induced angiogenesis) experimental models of inflammation. KEY RESULTS A network of polar interactions stabilized by a direct ionic bond between DF 2156A and Lys 99 on CXCR1 and the non‐conserved residue Asp 293 on CXCR2 are the key determinants of DF 2156A binding. DF 2156A acted as a non‐competitive allosteric inhibitor blocking the signal transduction leading to chemotaxis without altering the binding affinity of natural ligands. DF 2156A effectively and selectively inhibited CXCR1/CXCR2‐mediated chemotaxis of L1.2 transfectants and leucocytes. In a murine model of sponge‐induced angiogenesis, DF 2156A reduced leucocyte influx, TNF‐α production and neovessel formation. In vitro, DF 2156A prevented proliferation, migration and capillary‐like organization of HUVECs in response to human IL‐8. In a rat model of liver ischaemia and reperfusion (I/R) injury, DF 2156A decreased PMN and monocyte‐macrophage infiltration and associated hepatocellular injury. CONCLUSION AND IMPLICATIONS DF 2156A is a non‐competitive allosteric inhibitor of both IL‐8 receptors CXCR1 and CXCR2. It prevented experimental angiogenesis and hepatic I/R injury in vivo and, therefore, has therapeutic potential for acute and chronic inflammatory diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01566.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 74

Metadata

Authors
Bertini, R., Barcelos, L., Beccari, A., Cavalieri, B., Moriconi, A., Bizzarri, C., Di Benedetto, P., Di Giacinto, C., Gloaguen, I., Galliera, E., Corsi, M., Russo, R., Andrade, S., Cesta, M., Nano, G., Aramini, A., Cutrin, J., Locati, M., Allegretti, M., & Teixeira, M.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2011-12-16
Volume
165
Issue
2
Pages
436-454
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1605318550
Cited by
74
References
5
FWCI
2.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01566.x
The paper
Bertini, R., Barcelos, L., Beccari, A., Cavalieri, B., Moriconi, A., Bizzarri, C., Di Benedetto, P., Di Giacinto, C., Gloaguen, I., Galliera, E., Corsi, M., Russo, R., Andrade, S., Cesta, M., Nano, G., Aramini, A., Cutrin, J., Locati, M., Allegretti, M., & Teixeira, M. (2012). Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01566.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.